These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2758 related articles for article (PubMed ID: 32903482)

  • 41. Allogeneic CAR-T cells for cancer immunotherapy.
    Chen X; Gao Y; Zhang Y
    Immunotherapy; 2024; 16(16-17):1079-1090. PubMed ID: 39378059
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.
    Fix SM; Jazaeri AA; Hwu P
    Cancer Discov; 2021 Mar; 11(3):560-574. PubMed ID: 33563662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
    Lanitis E; Rota G; Kosti P; Ronet C; Spill A; Seijo B; Romero P; Dangaj D; Coukos G; Irving M
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33156338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
    Perez C; Gruber I; Arber C
    Front Immunol; 2020; 11():583716. PubMed ID: 33262761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
    Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
    Front Immunol; 2021; 12():780145. PubMed ID: 34975869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
    Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
    [No Abstract]   [Full Text] [Related]  

  • 47. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tuning the performance of CAR T cell immunotherapies.
    Richardson NH; Luttrell JB; Bryant JS; Chamberlain D; Khawaja S; Neeli I; Radic M
    BMC Biotechnol; 2019 Nov; 19(1):84. PubMed ID: 31783836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in off-the-shelf CAR T-cell therapy.
    Benjamin R
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
    [No Abstract]   [Full Text] [Related]  

  • 50. Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.
    Chen S; van den Brink MRM
    Best Pract Res Clin Haematol; 2024 Sep; 37(3):101566. PubMed ID: 39396256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
    Huang D; Miller M; Ashok B; Jain S; Peppas NA
    Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.
    Bui TA; Mei H; Sang R; Ortega DG; Deng W
    EBioMedicine; 2024 Aug; 106():105266. PubMed ID: 39094262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
    Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
    Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Universal CARs, universal T cells, and universal CAR T cells.
    Zhao J; Lin Q; Song Y; Liu D
    J Hematol Oncol; 2018 Nov; 11(1):132. PubMed ID: 30482221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
    Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
    Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Engineering immune-evasive allogeneic cellular immunotherapies.
    Martin KE; Hammer Q; Perica K; Sadelain M; Malmberg KJ
    Nat Rev Immunol; 2024 Sep; 24(9):680-693. PubMed ID: 38658708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 138.